3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
4
trastuzumab deruxtecan
3
fludarabine
3
Standard of Care
3
Injections
3
Cisplatin
3
Bevacizumab
3
toripalimab
2
sacituzumab govitecan
2
pembrolizumab
2
fludarabine phosphate
2
Specimen Handling
2
Radiosurgery
2
Pemetrexed
2
Palliative Care
2
Gemcitabine
2
Fulvestrant
2
Fluorouracil
2
Docetaxel
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
vedolizumab
1
tislelizumab
1
sintilimab
1
lobaplatin
1
lenvatinib
1
ivosidenib
1
irinotecan sucrosofate
1
exemestane
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Neoplasm Metastasis
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled